NCT07414914 Self-Myofascial Release Plus Exercise Versus Exercise Alone in Type 2 Diabetes
| NCT ID | NCT07414914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Izmir Katip Celebi University |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2026-05-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-11-03 with a primary completion date of 2026-05-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to investigate the effects of adding self-myofascial release applied to the plantar fascia and gastrosoleus muscles to an exercise program on foot function, physical performance, and plantar fascia thickness in individuals with type 2 diabetes. Participants aged 30 to 65 years with controlled type 2 diabetes will be randomly allocated to either an exercise-only group or an exercise plus self-myofascial release group. Both groups will complete an eight-week supervised exercise program three times per week. The intervention group will additionally perform self-myofascial release using a foam roller before exercise sessions. Outcomes will include foot function, balance, functional mobility, gait performance, and plantar fascia thickness assessed by ultrasonography before and after the intervention.
Eligibility Criteria
Inclusion Criteria: * Individuals aged 30 to 65 years * Diagnosed with type 2 diabetes mellitus for at least 1 year * Controlled type 2 diabetes mellitus * Able to ambulate independently without assistive devices Exclusion Criteria: * Severe pes planus or pes cavus defined by the Foot Posture Index-6 (FPI-6) (score ≥ +10 or ≤ -5) * History of plantar fasciitis * Plantar fascia ulceration * Peripheral neuropathy * Diagnosed peripheral vascular disease * History of lower extremity surgery or fracture during last year * Rheumatologic or connective tissue disorders affecting soft tissue properties * Neurological or diagnosed cognitive disorders * Pregnancy * Other types of diabetes mellitus * Obesity (BMI \> 30 kg/m²) * Serious cardiopulmonary disorders, including heart failure, history of myocardial infarction, or severe chronic obstructive pulmonary disease or asthma
Contact & Investigator
Sevtap GUNAY UÇURUM, Prof
STUDY DIRECTOR
Izmir Katip Celebi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
Frequently Asked Questions
Who can join the NCT07414914 clinical trial?
This trial is open to female participants only, aged 30 Years or older, up to 65 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07414914 currently recruiting?
Yes, NCT07414914 is actively recruiting participants. Contact the research team at SumenaHareket4@gmail.com for enrollment information.
Where is the NCT07414914 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT07414914 clinical trial?
NCT07414914 is sponsored by Izmir Katip Celebi University. The principal investigator is Sevtap GUNAY UÇURUM, Prof at Izmir Katip Celebi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.